In a report released yesterday, David S Macdonald from SunTrust Robinson reiterated a Buy rating on American Renal Associates Holdings Inc (NYSE: ARA), with a price target of $25. The company’s shares closed yesterday at $20.03.
According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 16.6% and a 74.8% success rate. Macdonald covers the Services sector, focusing on stocks such as Encompass Health Corporation, Walgreens Boots Alliance, and WellCare Health Plans.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for American Renal Associates Holdings Inc with a $20.50 average price target.
See today’s analyst top recommended stocks >>
Based on American Renal Associates Holdings Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $18.89 million. In comparison, last year the company had a GAAP net loss of $4.63 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
American Renal Associates Holdings, Inc. operates with interest in providing kidney dialysis services. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure.
